CN103788053B - 布雷菲德菌素a酯类衍生物及其制备与应用 - Google Patents
布雷菲德菌素a酯类衍生物及其制备与应用 Download PDFInfo
- Publication number
- CN103788053B CN103788053B CN201210426089.9A CN201210426089A CN103788053B CN 103788053 B CN103788053 B CN 103788053B CN 201210426089 A CN201210426089 A CN 201210426089A CN 103788053 B CN103788053 B CN 103788053B
- Authority
- CN
- China
- Prior art keywords
- brefeldin
- compound
- formula
- add
- ddd
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- -1 Brefeldin A ester Chemical class 0.000 title claims abstract description 36
- JUMGSHROWPPKFX-UHFFFAOYSA-N brefeldin-A Natural products CC1CCCC=CC2(C)CC(O)CC2(C)C(O)C=CC(=O)O1 JUMGSHROWPPKFX-UHFFFAOYSA-N 0.000 title claims abstract description 20
- 238000002360 preparation method Methods 0.000 title claims abstract description 17
- 238000000034 method Methods 0.000 claims abstract description 8
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 claims description 36
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 24
- 238000003756 stirring Methods 0.000 claims description 24
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical class ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 claims description 18
- 229960000549 4-dimethylaminophenol Drugs 0.000 claims description 18
- 238000006243 chemical reaction Methods 0.000 claims description 18
- 239000000376 reactant Substances 0.000 claims description 14
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 8
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 8
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 6
- 241000894006 Bacteria Species 0.000 claims description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 6
- 239000003205 fragrance Substances 0.000 claims description 6
- 239000003960 organic solvent Substances 0.000 claims description 6
- 239000003054 catalyst Substances 0.000 claims description 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 4
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 claims description 4
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 4
- MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 claims description 4
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 4
- 229910052736 halogen Inorganic materials 0.000 claims description 4
- 150000002367 halogens Chemical class 0.000 claims description 4
- 125000001624 naphthyl group Chemical group 0.000 claims description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Substances C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 4
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 4
- 239000000126 substance Substances 0.000 claims description 4
- 125000002769 thiazolinyl group Chemical group 0.000 claims description 4
- 125000001544 thienyl group Chemical group 0.000 claims description 4
- 125000000304 alkynyl group Chemical group 0.000 claims description 3
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 3
- 238000000926 separation method Methods 0.000 claims description 3
- OCJBOOLMMGQPQU-UHFFFAOYSA-N 1,4-dichlorobenzene Chemical class ClC1=CC=C(Cl)C=C1 OCJBOOLMMGQPQU-UHFFFAOYSA-N 0.000 claims description 2
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 claims description 2
- 239000011261 inert gas Substances 0.000 claims description 2
- 230000035484 reaction time Effects 0.000 claims description 2
- 150000002240 furans Chemical class 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 abstract description 51
- 230000000694 effects Effects 0.000 abstract description 5
- 208000000461 Esophageal Neoplasms Diseases 0.000 abstract description 4
- 230000000259 anti-tumor effect Effects 0.000 abstract description 4
- 208000017897 Carcinoma of esophagus Diseases 0.000 abstract description 3
- 206010009944 Colon cancer Diseases 0.000 abstract description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 abstract description 3
- 208000029742 colonic neoplasm Diseases 0.000 abstract description 3
- 230000002401 inhibitory effect Effects 0.000 abstract description 3
- 210000003734 kidney Anatomy 0.000 abstract description 3
- 201000005202 lung cancer Diseases 0.000 abstract description 3
- 208000020816 lung neoplasm Diseases 0.000 abstract description 3
- 206010060862 Prostate cancer Diseases 0.000 abstract description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 abstract description 2
- 238000000338 in vitro Methods 0.000 abstract description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 72
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 37
- 238000005406 washing Methods 0.000 description 24
- KQNZDYYTLMIZCT-KQPMLPITSA-N brefeldin A Chemical compound O[C@@H]1\C=C\C(=O)O[C@@H](C)CCC\C=C\[C@@H]2C[C@H](O)C[C@H]21 KQNZDYYTLMIZCT-KQPMLPITSA-N 0.000 description 19
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 18
- 238000005160 1H NMR spectroscopy Methods 0.000 description 18
- 239000011734 sodium Substances 0.000 description 18
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 17
- 239000012043 crude product Substances 0.000 description 13
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 12
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 12
- 239000007864 aqueous solution Substances 0.000 description 12
- 238000001035 drying Methods 0.000 description 12
- 239000012074 organic phase Substances 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 238000012512 characterization method Methods 0.000 description 11
- 230000004044 response Effects 0.000 description 11
- 239000002904 solvent Substances 0.000 description 11
- 238000004809 thin layer chromatography Methods 0.000 description 8
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 6
- 239000012141 concentrate Substances 0.000 description 6
- 238000010790 dilution Methods 0.000 description 6
- 239000012895 dilution Substances 0.000 description 6
- 238000000605 extraction Methods 0.000 description 6
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 6
- WPYMKLBDIGXBTP-UHFFFAOYSA-N Benzoic acid Natural products OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 4
- YGSDEFSMJLZEOE-UHFFFAOYSA-N Salicylic acid Natural products OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 4
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N biotin Natural products N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 3
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 239000005711 Benzoic acid Substances 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 235000010233 benzoic acid Nutrition 0.000 description 3
- 229960002685 biotin Drugs 0.000 description 3
- 235000020958 biotin Nutrition 0.000 description 3
- 239000011616 biotin Substances 0.000 description 3
- 229930016911 cinnamic acid Natural products 0.000 description 3
- 235000013985 cinnamic acid Nutrition 0.000 description 3
- 235000019253 formic acid Nutrition 0.000 description 3
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 3
- PVNIIMVLHYAWGP-UHFFFAOYSA-N nicotinic acid Natural products OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 3
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 229960004889 salicylic acid Drugs 0.000 description 3
- 230000001093 anti-cancer Effects 0.000 description 2
- 230000000118 anti-neoplastic effect Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000003120 macrolide antibiotic agent Substances 0.000 description 2
- 229960003512 nicotinic acid Drugs 0.000 description 2
- 235000001968 nicotinic acid Nutrition 0.000 description 2
- 239000011664 nicotinic acid Substances 0.000 description 2
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 1
- 241000235349 Ascomycota Species 0.000 description 1
- QRWYRZXXGBZIHF-HYARGMPZSA-N CCCCCSCC(C(C)NC1=O)N1/N=C(\C)/CCNC(OC(C)(C)C)=O Chemical compound CCCCCSCC(C(C)NC1=O)N1/N=C(\C)/CCNC(OC(C)(C)C)=O QRWYRZXXGBZIHF-HYARGMPZSA-N 0.000 description 1
- 0 C[C@@](CCCC=CC=N)OC(C=C[C@]([C@](CC1)C[C@]1OC(*)=O)O*)=O Chemical compound C[C@@](CCCC=CC=N)OC(C=C[C@]([C@](CC1)C[C@]1OC(*)=O)O*)=O 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- 206010019851 Hepatotoxicity Diseases 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 241000985535 Penicillium decumbens Species 0.000 description 1
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- JIMXXGFJRDUSRO-UHFFFAOYSA-N adamantane-1-carboxylic acid Chemical compound C1C(C2)CC3CC2CC1(C(=O)O)C3 JIMXXGFJRDUSRO-UHFFFAOYSA-N 0.000 description 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000001857 anti-mycotic effect Effects 0.000 description 1
- 230000001679 anti-nematodal effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000002543 antimycotic Substances 0.000 description 1
- 229940125648 antineoplastic drug candidate Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 125000003963 dichloro group Chemical group Cl* 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000007686 hepatotoxicity Effects 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- 229940041033 macrolides Drugs 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- PYLWMHQQBFSUBP-UHFFFAOYSA-N monofluorobenzene Chemical compound FC1=CC=CC=C1 PYLWMHQQBFSUBP-UHFFFAOYSA-N 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000024053 secondary metabolic process Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- XJDNKRIXUMDJCW-UHFFFAOYSA-J titanium tetrachloride Chemical compound Cl[Ti](Cl)(Cl)Cl XJDNKRIXUMDJCW-UHFFFAOYSA-J 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D313/00—Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
本发明提供了一种具有抗肿瘤活性的布雷菲德菌素A酯类衍生物及其制备与应用,所述布雷菲德菌素A酯类衍生物结构如式(Ⅰ)所示。本发明新化合物对食管癌、肺癌、肾癌、结肠癌和前列腺癌有高效的疗效,在体外检测有效抑制率高达80%;获得本发明布雷菲德菌素A酯类衍生物的方法简单,易于操作。
Description
(一)技术领域
本发明涉及一类具有抗肿瘤活性的布雷菲德菌素A酯类衍生物及其制备与应用。
(二)背景技术
布雷菲德菌素A((+)BrefeldinABFA)是一种天然的大环内酯类抗生素,是Ascomycetes的二级代谢产物,又称斜卧菌素或壳二孢。1958年Singleton等人首次从Penicilliumdecumbens发酵液中分离得到。1971年,BFA的完全构型由X射线晶体结构分析得到确定。布雷菲德菌素A分子式C16H24O4,分子量280Da,分子结构含有5个手性中心,2个双键,1个五元碳环和1个13元大环内酯,结构如下所示:
布雷菲德菌素A具有多种生物活性,包括抗真菌、抗病毒、抗线虫、抗有丝分裂,并且发现它对多种癌细胞具有高活性抑制作用(GI50=0.04μM)。目前,布雷菲德菌素A作为一种重要的分子工具广泛应用于哺乳动物信号传导途径的研究。由于其生物功能的多样性和高效的抗癌生物活性,美国肿瘤研究院(NCI)将BFA作为抗肿瘤药物的重点研究,作为新型抗癌候选药物。但是,布雷菲德菌素A因其自身的药代动力学性质(生物利用度低、水溶性差、血浆半衰期短等)不理想,无法作为抗肿瘤治疗试剂应用于临床。为了克服这些缺陷,对BFA的结构修饰及衍生物研究逐渐受到重视,希望能寻找到既保持BFA高活性抗肿瘤作用又适合作为药物用于临床的化合物。
(三)发明内容
本发明的目的在于提供一类具有明显抗肿瘤活性的布雷菲德菌素A酯类化合物,对食管癌细胞有效抑制,GI50值高达0.35uM,以及一种简便的布雷菲德菌素A酯类衍生物的制备方法。
本发明采用的技术方案是:
一种布雷菲德菌素A酯类衍生物,其结构如式(Ⅰ)所示:
式(Ⅰ)中:
R1为-H或
R2为C1~C10烷基(优选为甲基或金刚烷基)、C3~C10烯基、C3~C10炔基、苯基、萘基、取代苯基、噻吩基、吡啶基、或所述取代苯基的取代基为羟基或卤素(优选为F)。
R1为时,式(Ⅰ)中出现的2个R2为完全相同的取代基。
所述布雷菲德菌素A酯类衍生物优选为下列之一:
本发明还涉及所述布雷菲德菌素A酯类衍生物的制备方法,所述方法包括:将式(Ⅱ)所示的布雷菲德菌A溶于有机溶剂中,在惰性气体的保护下,加入式(Ⅲ)所示羧酸和催化剂,在25℃~100℃下搅拌反应8h~32h,反应结束后,反应液经分离纯化得到式(Ⅰ)所示布雷菲德菌素A酯类衍生物;
式(Ⅲ)中,
R2为C1~C10烷基、C3~C10烯基、C3~C10炔基、苯基、萘基、取代苯基、噻吩基、吡啶基、或所述取代苯基的取代基为羟基或卤素;
所述有机溶剂为下列之一:N,N-二甲基甲酰胺、二氯甲烷、丙酮、四氢呋喃、乙腈、乙酸乙酯、氯仿、1,2-二氯乙烷、氯苯、对-二氯苯、苯、甲苯、正己烷、环己烷、石油醚、正戊烷、二甲苯、丙酮;
所述催化剂为下列之一:DCC/DMAP、EDC/DMAP、四氯化钛、二氯亚砜、对甲基苯磺酸、十氧化四磷。
涉及的反应式如下:
由于羟基酯化的程度不同,因此反应产物为两种结构,具体制备时可根据需要分离纯化其中的一种或两种产物。具体分离纯化步骤为:反应液加入适量二氯甲烷稀释,经水洗(2×10ml),饱和氯化钠溶液洗涤(2×10ml),合并的水相用乙酸乙酯萃取(1×30ml),合并有机相,无水硫酸钠干燥,过滤,浓缩得粗产物,粗产物经薄层层析分离获得需要的产物。
优选的,所述催化剂为EDC/DMAP,所述布雷菲德菌A、式(Ⅲ)所示羧酸、EDC、DMAP物质的量之比为1:2.0~2.3:3:0.5。
有机溶剂优选为二氯甲烷,用量为50~200mL/g布雷菲德菌A。
所述反应优选在30~50℃下进行,反应时间20~25h。
本发明还涉及所述的布雷菲德菌素A酯类衍生物在制备抗肿瘤药物中的应用。
优选的,所述抗肿瘤药物为防治食管癌、肺癌、结肠癌、肾癌或前列腺癌的药物。
本发明的有益效果主要体现在:本发明新化合物对食管癌、肺癌、肾癌、结肠癌和前列腺癌有高效的疗效,在体外检测有效抑制率高达80%;获得布雷菲德菌素A酯类衍生物的方法简单,易于操作。
(四)具体实施方式
下面结合具体实施例对本发明进行进一步描述,但本发明的保护范围并不仅限于此:
总反应式如下:
实施例1:7-O-乙酰-BFA(Ⅰ-1)、4,7-O-二乙酰-BFA(Ⅰ-2)的制备
向放置有磁力搅拌子的50mL的圆底烧瓶中加入10mL无水二氯甲烷(10ml),再加入BFA(100mg,0.36mmol),开始搅拌;后加入乙酸(45mg,0.75mmol)、EDC.HCl(1-乙基-(3-二甲基氨基丙基)碳酰二亚胺盐酸盐)(205mg,108mmol)、DMAP(4-二甲氨基吡啶)(22mg,0.18mmol),于40℃加热反应24h,终止反应。反应液加入10ml二氯甲烷稀释,经水洗(2×10ml),饱和氯化钠溶液洗涤(2×10ml),合并的水相用乙酸乙酯萃取(1×30ml),合并有机相,无水硫酸钠干燥,过滤,浓缩得粗产物,粗产物在展开剂E/P=1:5的条件下经薄层层析分离获得化合物(Ⅰ-1)(Rf=0.2,收率42.50%)和化合物(Ⅰ-2)(Rf=0.8,收率25.29%)。
化合物表征:
化合物(Ⅰ-1):1HNMR(500MHz,CDCl3)δ7.24(dd,J=15.7,3.3Hz,1H),5.73–5.66(m,2H),5.29(dd,J=10.6,4.5Hz,1H),5.27–5.22(m,1H),4.84(dqd,J=12.4,6.2,1.5Hz,1H),4.34–4.26(m,1H),2.44–2.36(m,1H)2.25(m,1H),2.17(m,1H),2.00(m,3H),1.84(m,2H),1.60-1.75(m,2H),1.50-1.60(m,4H),1.25(d,J=6.29Hz,3H),0.96–0.87(m,1H).13CNMR(126MHz,CDCl3)δ170.03,165.73,147.33,136.31,130.55,118.11,72.25,71.92,58.37,49.42,44.29,43.18,40.87,34.04,31.77,26.57,20.80,18.36.ESI-MS:m/z345(M+Na)+
化合物(Ⅰ-2):1HNMR(500MHz,CDCl3)δ7.22(dd,J=15.7,3.4Hz,1H),5.75–5.65(m,2H),5.27–5.17(m,2H),5.10(tt,J=5.5,2.8Hz,1H),4.84(dqd,J=12.4,6.2,1.6Hz,1H),2.44(td,J=16.3,9.4Hz,1H),2.30(ddd,J=14.9,9.6,5.6Hz,1H),2.10-2.08(m,2H),2.06-2.02(m,2H),1.98(dd,J=4.4,2.5Hz,3H),1.88–1.81(m,2H),1.77–1.63(m,2H),1.59(dddd,J=14.4,6.5,3.7,1.4Hz,2H),1.56–1.47(m,2H),1.25(d,J=6.29Hz,3H),0.97–0.88(m,1H).13CNMR(126MHz,CDCl3)δ170.70,169.92,165.72,147.15,135.71,131.13,118.31,75.21,71.91,58.24,49.68,44.05,40.02,38.28,34.05,31.72,26.50,21.26,20.74,18.32.ESI-MS:m/z387(M+Na)+
实施例2:7-O-(苯甲酸)酰-BFA(Ⅰ-3)、4,7-O-二(苯甲酸)酰-BFA(Ⅰ-4)的制备
向放置有磁力搅拌子的50mL的圆底烧瓶中加入10mL无水二氯甲烷(10ml),再加入BFA(100mg,0.36mmol),开始搅拌;后加入苯甲酸(91.5mg,0.75mmol)、EDC.HCl(205mg,108mmol)、DMAP(22mg,0.18mmol),于40℃加热反应24h,终止反应。反应液加入10ml二氯甲烷稀释,经水洗(2×10ml),饱和氯化钠溶液洗涤(2×10ml),合并的水相用乙酸乙酯萃取(1×30ml),合并有机相,无水硫酸钠干燥,过滤,浓缩得粗产物,粗产物在展开剂E/P=1:5的条件下经薄层层析分离获得化合物(Ⅰ-3)(Rf=0.2,收率46.7%)和化合物(Ⅰ-4)(Rf=0.8收率,29.6%)。
化合物表征:
化合物(Ⅰ-3):1HNMR(500MHz,CDCl3)δ8.07(dd,J=8.3,1.2Hz,2H),7.61–7.56(m,1H),7.48–7.43(m,2H),7.35(dd,J=15.7,3.3Hz,1H),5.79–5.70(m,2H),5.50(ddd,J=10.5,3.1,1.9Hz,1H),5.34(dd,J=15.2,9.6Hz,1H),4.88–4.80(m,1H),4.34–4.28(m,1H),2.53–2.44(m,1H),2.34(dt,J=18.3,9.0Hz,1H),2.23(ddd,J=14.2,9.3,5.2Hz,1H),2.01–1.96(m,2H),1.89–1.81(m,2H),1.77–1.65(m,2H),1.58–1.49(m,2H),1.23(d,J=6.3Hz,3H),0.93(tdd,J=11.6,8.1,3.6Hz,1H).13CNMR(126MHz,CDCl3)δ165.66,165.42,147.31,136.40,133.32,130.54,129.63,129.47,129.43,128.45,128.31,118.18,76.88,72.20,71.83,49.65,44.27,43.08,40.96,33.98,31.73,26.56,20.70.ESI-MS:m/z407(M+Na)+
化合物(Ⅰ-4):1HNMR(500MHz,CDCl3)δ8.14–8.06(m,2H),8.07–8.01(m,2H),7.59(dd,J=13.7,7.4Hz,2H),7.47(td,J=7.8,2.8Hz,4H),7.40(dd,J=15.7,3.3Hz,1H),5.87–5.76(m,2H),5.60(ddd,J=10.4,3.1,1.8Hz,1H),5.49–5.40(m,1H),5.36(dd,J=15.2,9.6Hz,1H),4.94–4.83(m,1H),2.74–2.59(m,1H),2.49(ddd,J=15.0,9.9,5.5Hz,1H),2.44–2.35(m,1H),2.30(dd,J=14.0,7.5Hz,1H),2.10–2.00(m,1H),1.93–1.90(m,1H),1.89(d,J=3.9Hz,1H),1.87(d,J=5.5Hz,1H),1.81(dd,J=5.5,2.6Hz,1H),1.76(dd,J=15.2,7.7Hz,1H),1.64–1.51(m,1H),1.27(d,J=6.2Hz,3H),0.99(dd,J=20.6,13.5Hz,1H).13CNMR(126MHz,CDCl3)δ165.90,165.55,165.30,147.06,135.74,133.35,132.93,131.22,130.35,129.67,129.47,129.39,128.46,128.35,118.48,76.74,75.95,71.80,50.23,44.15,40.08,38.56,34.02,31.77,26.52,20.71.ESI-MS:m/z511(M+Na)+
实施例3:7-O-(对氟苯甲酸)酰-BFA(Ⅰ-5)、4,7-O-二(对氟苯甲酸)酰-BFA(Ⅰ-6)的制备
向放置有磁力搅拌子的50mL的圆底烧瓶中加入10mL无水二氯甲烷(10ml),再加入BFA(100mg,0.36mmol),开始搅拌;后加入4-氟苯甲酸(105mg,0.75mmol)、EDC.HCl(205mg,108mmol)、DMAP(22mg,0.18mmol),于40℃加热反应24h,终止反应。反应液加入10ml二氯甲烷稀释,经水洗(2×10ml),饱和氯化钠溶液洗涤(2×10ml),合并的水相用乙酸乙酯萃取(1×30ml),合并有机相,无水硫酸钠干燥,过滤,浓缩得粗产物,粗产物在展开剂E/P=1:5的条件下经薄层层析分离获得化合物(Ⅰ-5)(Rf=0.2,收率36.4%)和化合物(Ⅰ-6)(Rf=0.8,收率20.0%)。
化合物表征:
化合物(Ⅰ-5):1HNMR(500MHz,CDCl3)δ8.12–8.08(m,2H),7.35(dd,J=15.7,3.3Hz,1H),7.17–7.12(m,2H),5.79–5.72(m,2H),5.50(ddd,J=10.5,3.1,1.9Hz,1H),5.35(dd,J=15.2,9.6Hz,1H),4.86(dqd,J=12.4,6.2,1.4Hz,1H),4.37–4.32(m,1H),2.55–2.47(m,1H),2.34(dt,J=18.3,9.2Hz,1H),2.26(ddd,J=14.2,9.4,5.1Hz,1H),2.05–2.01(m,1H),1.89–1.85(m,1H),1.80–1.74(m,1H),1.73–1.71(m,1H),1.71–1.66(m,1H),1.62(s,1H),1.59–1.52(m,2H),1.27–1.23(m,3H),0.95(ddd,J=13.7,11.2,6.9Hz,1H).13CNMR(126MHz,CDCl3)δ167.04,165.67,164.51,147.15,136.40,132.33,132.26,130.81,125.96,118.29,115.82,115.64,77.08,72.40,71.94,49.72,44.36,43.21,41.08,34.07,31.81,26.63,20.78.ESI-MS:m/z425(M+Na)+
化合物(Ⅰ-6):1HNMR(500MHz,CDCl3)δ8.12–8.07(m,2H),8.06–8.02(m,2H),7.38(dd,J=15.7,3.3Hz,1H),7.16–7.11(m,4H),5.85–5.77(m,2H),5.57(ddd,J=10.4,3.2,1.8Hz,1H),5.43–5.38(m,1H),5.36–5.29(m,1H),4.88(dqd,J=12.3,6.0,1.3Hz,1H),2.64(qd,J=9.4,6.5Hz,1H),2.48(ddd,J=15.0,9.8,5.5Hz,1H),2.40–2.31(m,1H),2.29–2.23(m,1H),2.08–2.00(m,1H),1.94–1.85(m,3H),1.84–1.76(m,2H),1.60–1.52(m,1H),1.26(d,J=6.3Hz,3H),0.98(td,J=13.6,6.9Hz,1H).13CNMR(126MHz,CDCl3)δ167.01,166.76,165.53,165.00,164.36,146.84,135.56,132.31,132.23,132.06,131.98,131.43,126.57,126.55,125.64,118.59,115.79,115.61,115.44,76.90,76.09,71.91,50.16,44.16,40.09,38.50,34.04,31.79,26.51,20.70.ESI-MS:m/z547(M+Na)+
实施例4:7-O-(肉桂酸酸)酰-BFA(Ⅰ-7)、4,7-O-二(肉桂酸)酰BFA(Ⅰ-8)的制备
向放置有磁力搅拌子的50mL的圆底烧瓶中加入10mL无水二氯甲烷(10ml),再加入BFA(100mg,0.36mmol),开始搅拌;后加入肉桂酸(111mg,0.75mmol)、EDC.HCl(205mg,108mmol)、DMAP(22mg,0.18mmol),于40℃加热反应24h,终止反应。反应液加入10ml二氯甲烷稀释,经水洗(2×10ml),饱和氯化钠溶液洗涤(2×10ml),合并的水相用乙酸乙酯萃取(1×30ml),合并有机相,无水硫酸钠干燥,过滤,浓缩得粗产物,粗产物在展开剂E/P=1:5的条件下经薄层层析分离获得化合物(Ⅰ-7)(Rf=0.2,收率41.1%)和化合物(Ⅰ-8)(Rf=0.8,收率37.3%)。
化合物表征:
化合物(Ⅰ-7):1HNMR(500MHz,CDCl3)δ7.73(d,J=16.0Hz,1H),7.53(dd,J=6.3,3.2Hz,1H),7.42–7.37(m,1H),7.31(dd,J=15.7,3.2Hz,1H),6.47(d,J=16.0Hz,1H),5.78–5.68(m,1H),5.39(ddd,J=10.5,2.9,1.9Hz,1H),5.31(dd,J=14.7,9.2Hz,1H),4.88–4.80(m,1H),4.34–4.28(m,1H),2.50–2.39(m,1H),2.23(tt,J=9.0,7.0Hz,1H),2.02–1.96(m,1H),1.84(dd,J=18.9,7.5Hz,1H),1.73(dd,J=14.6,7.4Hz,1H),1.70–1.64(m,1H),1.53(dt,J=19.7,6.7Hz,1H),1.24(s,1H),0.97–0.88(m,1H).13CNMR(126MHz,CDCl3)δ165.83,165.73,147.39,145.72,136.38,134.08,130.54,130.51,128.89,128.14,118.16,117.28,76.42,72.19,71.82,49.56,44.28,43.12,40.92,34.00,31.74,26.57,20.73.ESI-MS:m/z433(M+Na)+
化合物(Ⅰ-8):1HNMR(500MHz,CDCl3)δ7.71(dd,J=34.5,16.0Hz,1H),7.56–7.52(m,2H),7.40(dd,J=6.6,3.4Hz,3H),7.34(dd,J=15.7,3.3Hz,1H),6.46(dd,J=28.2,16.0Hz,1H),5.82–5.74(m,1H),5.47–5.42(m,1H),5.30(dt,J=10.9,8.0Hz,1H),4.91–4.84(m,1H),2.56(td,J=16.1,9.3Hz,1H),2.42(ddd,J=14.9,9.7,5.6Hz,1H),2.31–2.18(m,2H),2.08–2.01(m,1H),1.93–1.84(m,3H),1.74(dt,J=14.7,6.7Hz,2H),1.60–1.51(m,1H),1.24(d,J=6.3Hz,3H),0.97(td,J=13.7,9.0Hz,1H).13CNMR(126MHz,CDCl3)δ166.43,165.72,165.65,147.19,145.88,144.79,135.83,134.31,134.10,131.13,130.52,130.30,128.89,128.86,128.17,128.05,118.41,118.24,117.20,76.31,75.38,71.80,49.99,44.15,40.15,38.49,34.07,31.75,26.54,20.72.ESI-MS:m/z563(M+Na)+
实施例5:7-O-(α-噻吩甲酸)酰-BFA(Ⅰ-9)、4,7-O-二(α-噻吩甲酸)酰BFA(Ⅰ-10)的制备
向放置有磁力搅拌子的50mL的圆底烧瓶中加入10mL无水二氯甲烷(10ml),再加入BFA(100mg,0.36mmol),开始搅拌;后加入2-噻吩甲酸(96mg,0.75mmol)、EDC.HCl(205mg,108mmol)、DMAP(22mg,0.18mmol),于40℃加热反应24h,终止反应。反应液加入10ml二氯甲烷稀释,经水洗(2×10ml),饱和氯化钠溶液洗涤(2×10ml),合并的水相用乙酸乙酯萃取(1×30ml),合并有机相,无水硫酸钠干燥,过滤,浓缩得粗产物,粗产物在展开剂E/P=1:5的条件下经薄层层析分离获得化合物(Ⅰ-9)(Rf=0.2,收率40.3%)和化合物(Ⅰ-10)(Rf=0.8,收率39.6%)。
化合物表征:
化合物(Ⅰ-9):1HNMR(500MHz,CDCl3)δ7.83(d,J=2.9Hz,1H),7.59(d,J=4.9Hz,1H),7.31(dd,J=15.7,3.2Hz,1H),7.14–7.10(m,1H),5.82–5.68(m,2H),5.47–5.41(m,1H),5.32(dd,J=15.2,9.6Hz,1H),4.83(dd,J=9.6,6.1Hz,1H),4.33–4.28(m,1H),2.50–2.40(m,1H),2.30(dt,J=18.2,8.9Hz,1H),2.22(ddd,J=14.2,9.3,5.2Hz,1H),1.99(dd,J=15.2,5.8Hz,2H),1.84(t,J=9.3Hz,2H),1.76–1.64(m,2H),1.52(dt,J=9.5,5.8Hz,2H),1.23(d,J=6.3Hz,3H),0.98–0.86(m,1H).13CNMR(126MHz,CDCl3)δ165.64,161.09,147.09,136.34,133.86,132.98,132.87,130.53,127.88,118.26,76.30,72.17,71.85,49.55,44.23,43.02,40.88,33.96,31.70,26.53,20.68.ESI-MS:m/z413(M+Na)+
化合物(Ⅰ-10):1HNMR(500MHz,CDCl3)δ7.84(dd,J=3.8,1.2Hz,1H),7.79(dd,J=3.7,1.2Hz,1H),7.59(dd,J=5.0,1.2Hz,1H),7.56(dd,J=5.0,1.2Hz,1H),7.35(dd,J=15.7,3.3Hz,1H),7.11(td,J=4.9,3.9Hz,2H),5.86–5.74(m,2H),5.52(ddd,J=10.2,3.1,1.9Hz,1H),5.39–5.35(m,1H),5.35–5.29(m,1H),4.89–4.82(m,1H),2.60(qd,J=9.5,6.3Hz,1H),2.42(ddd,J=14.9,9.8,5.4Hz,1H),2.29(tdd,J=9.5,7.1,4.9Hz,2H),2.03(ddd,J=12.9,7.1,3.5Hz,1H),1.86(tdd,J=13.8,9.0,5.0Hz,3H),1.82–1.70(m,2H),1.60–1.50(m,1H),1.24(d,J=6.3Hz,3H),1.00–0.90(m,1H).13CNMR(126MHz,CDCl3)δ165.48,161.50,160.92,146.75,135.58,133.91,133.28,133.00,132.72,132.32,131.16,127.86,127.71,118.53,77.28,76.21,71.81,50.01,43.98,39.92,38.33,33.95,31.74,26.46,20.67.ESI-MS:m/z523(M+Na)+
实施例6:7-O-(α-奈甲酸)酰-BFA(Ⅰ-11)、4,7-O-二(α-奈甲酸)酰BFA(Ⅰ-12)的制备
向放置有磁力搅拌子的50mL的圆底烧瓶中加入10mL无水二氯甲烷(10ml),再加入BFA(100mg,0.36mmol),开始搅拌;后加入1-奈甲酸(129mg,0.75mmol)、EDC.HCl(205mg,108mmol)、DMAP(22mg,0.18mmol),于40℃加热反应24h,终止反应。反应液加入10ml二氯甲烷稀释,经水洗(2×10ml),饱和氯化钠溶液洗涤(2×10ml),合并的水相用乙酸乙酯萃取(1×30ml),合并有机相,无水硫酸钠干燥,过滤,浓缩得粗产物,粗产物在展开剂E/P=1:5的条件下经薄层层析分离获得化合物(Ⅰ-11)(Rf=0.2,收率39.6%)和化合物(Ⅰ-12)(Rf=0.8,收率30.1%)。
化合物表征:
化合物(Ⅰ-11):1HNMR(500MHz,CDCl3)δ8.91(d,J=8.7Hz,1H),8.14(d,J=7.2Hz,1H),8.02(d,J=8.2Hz,1H),7.89(d,J=8.2Hz,1H),7.61(t,J=8.2Hz,1H),7.56–7.48(m,2H),7.37(dd,J=15.6,3.1Hz,1H),5.94(dd,J=15.7,1.7Hz,1H),5.73(ddd,J=15.0,10.3,4.5Hz,1H),5.49(m,1H),5.27(dd,J=15.6,9.1Hz,1H),4.85(td,J=12.2,6.1Hz,1H),4.17(d,J=6.8Hz,1H),2.54–2.36(m,3H),2.05–1.95(m,3H),1.93–1.77(m,3H),1.76–1.67(m,1H),1.60–1.48(m,1H),1.26(d,J=5.9Hz,3H),0.93(td,J=13.3,5.5Hz,1H).13CNMR(126MHz,CDCl3)δ167.17,166.32,151.70,135.93,133.81,133.34,131.29,130.95,130.09,128.54,127.72,127.28,126.20,125.70,124.50,117.67,76.00,75.78,71.78,52.30,44.03,40.24,38.79,34.05,31.78,26.59,20.80.ESI-MS:m/z457(M+Na)+
化合物(Ⅰ-12):1HNMR(500MHz,CDCl3)δ8.98(dd,J=19.6,8.6Hz,2H),8.31(dd,J=7.3,0.8Hz,1H),8.19(dd,J=7.2,0.9Hz,1H),8.04(t,J=8.0Hz,2H),7.89(d,J=8.2Hz,2H),7.63(ddd,J=10.2,8.4,1.1Hz,2H),7.57–7.49(m,4H),7.44(dd,J=15.7,3.4Hz,1H),5.92(dd,J=15.7,1.6Hz,1H),5.80(ddd,J=14.9,10.1,4.6Hz,1H),5.73–5.69(m,1H),5.58–5.54(m,1H),5.37(dd,J=15.1,9.5Hz,1H),4.90(dq,J=12.4,6.3Hz,1H),2.69–2.60(m,1H),2.54(ddd,J=14.9,10.2,5.4Hz,1H),2.50–2.41(m,2H),2.09–1.99(m,2H),1.94–1.81(m,3H),1.80–1.69(m,1H),1.57(ddd,J=14.7,10.8,4.5Hz,1H),1.29(d,J=6.2Hz,3H),0.97(td,J=13.4,5.3Hz,1H).
13CNMR(126MHz,CDCl3)δ166.81,165.93,165.55,147.21,135.52,133.81,133.71,133.68,133.28,131.34,131.20,131.18,130.20,129.94,128.50,128.44,127.90,127.62,127.04,126.20,126.10,125.94,125.55,125.45,124.36,124.34,118.42,76.74,75.84,71.77,50.07,44.11,40.15,38.54,33.89,31.63,26.38,20.61.ESI-MS:m/z611(M+Na)+
实施例7:7-O-(水杨酸)酰-BFA(Ⅰ-13)、4,7-O-二(水杨酸)酰BFA(Ⅰ-14)的制备
向放置有磁力搅拌子的50mL的圆底烧瓶中加入10mL无水二氯甲烷(10ml),再加入BFA(100mg,0.36mmol),开始搅拌;后加入水杨酸(104mg,0.75mmol)、EDC.HCl(205mg,108mmol)、DMAP(22mg,0.18mmol),于40℃加热反应24h,终止反应。反应液加入10ml二氯甲烷稀释,经水洗(2×10ml),饱和氯化钠溶液洗涤(2×10ml),合并的水相用乙酸乙酯萃取(1×30ml),合并有机相,无水硫酸钠干燥,过滤,浓缩得粗产物,粗产物在展开剂E/P=1:5的条件下经薄层层析分离获得化合物(Ⅰ-13)(Rf=0.2,收率28.4%)和化合物(Ⅰ-14)(Rf=0.8,收率19.5%)。
化合物表征:
化合物(Ⅰ-13):1HNMR(500MHz,CDCl3)δ10.84(s,1H),10.61(s,1H),7.79(dd,J=7.9,1.3Hz,1H),7.51–7.42(m,2H),7.38(dt,J=3.1,1.7Hz,1H),,6.98(dd,J=11.9,8.5Hz,2H),6.90(dt,J=12.9,7.7Hz,2H),5.93(dd,J=15.7,1.8Hz,1H),5.80–5.70(m,2H),5.34(dd,J=15.2,9.6Hz,1H),5.24(dd,J=15.1,9.1Hz,1H),4.90–4.82(m,2H),2.70–2.62(m,2H),2.50(ddd,J=15.1,9.9,5.5Hz,1H),2.44–2.36(m,1H),2.19(s,1H),2.07–2.04(m,1H),1.95–1.85(m,4H),1.84–1.73(m,2H),1.61–1.52(m,1H),1.26(d,J=5.4Hz,3H),1.03–0.93(m,1H).
13CNMR(126MHz,CDCl3)δ169.79,166.23,151.60,146.60,136.36,136.20,135.81,135.71,131.15,130.79,129.83,117.83,75.68,71.79,69.59,49.61,43.92,40.10,38.79,34.11,31.82,26.60,20.83ESI-MS:m/z423(M+Na)+
化合物(Ⅰ-14):1HNMR(500MHz,CDCl3)δ10.80(s,1H),10.58(s,1H),7.92(dd,J=8.0,1.7Hz,1H),7.82(dd,J=8.0,1.7Hz,1H),7.49(dddd,J=10.0,8.7,7.4,1.7Hz,2H),7.36(dd,J=15.7,3.4Hz,1H),7.02–6.98(m,2H),6.95–6.90(m,2H),5.82(ddd,J=13.7,7.9,3.2Hz,2H),5.61(ddd,J=10.4,3.3,1.8Hz,1H),5.46(tt,J=5.5,2.9Hz,1H),5.33(dd,J=15.2,9.6Hz,1H),4.89(dqd,J=12.3,6.1,1.4Hz,1H),2.70–2.62(m,2H),2.50(ddd,J=15.1,9.9,5.5Hz,1H),2.44–2.36(m,1H),2.19(s,1H),2.07–2.04(m,1H),1.95–1.85(m,4H),1.84–1.73(m,2H),1.61–1.52(m,1H),1.26(d,J=5.4Hz,3H),1.03–0.93(m,1H).13CNMR(126MHz,CDCl3)δ169.68,169.02,165.44,162.03,161.84,146.15,136.35,135.85,135.37,131.80,129.78,129.77,119.48,119.24,119.07,117.87,117.74,112.57,111.75,77.13,76.57,72.09,50.10,44.21,40.11,38.55,34.16,31.86,26.54,20.79.ESI-MS:m/z423(M+Na)+
实施例8:7-O-(生物素)酰-BFA(Ⅰ-15)的制备
向放置有磁力搅拌子的50mL的圆底烧瓶中加入10mL无水二氯甲烷(10ml),再加入BFA(100mg,0.36mmol),开始搅拌;后加入维生素H(183mg,0.75mmol)、EDC.HCl(205mg,108mmol)、DMAP(22mg,0.18mmol),于40℃加热反应24h,终止反应。反应液加入10ml二氯甲烷稀释,经水洗(2×10ml),饱和氯化钠溶液洗涤(2×10ml),合并的水相用乙酸乙酯萃取(1×30ml),合并有机相,无水硫酸钠干燥,过滤,浓缩得粗产物,粗产物在展开剂DCM/CH3OH=1:8的条件下经薄层层析分离获得化合物(Ⅰ-15)(Rf=0.6,收率45.2%)。
化合物表征:
化合物(Ⅰ-15):1HNMR(500MHz,CDCl3)δ7.23(dd,J=15.7,3.3Hz,1H),6.65(s,1H),6.11(s,1H),5.66(dd,J=15.7,1.8Hz,1H),5.25(ddd,J=12.0,10.0,6.2Hz,2H),4.85–4.77(m,1H),4.48(dd,J=7.2,5.1Hz,1H),4.27(dd,J=16.8,9.4Hz,2H),3.39(d,J=18.5Hz,1H),3.13(dd,J=11.7,7.3Hz,1H),2.87(dd,J=12.8,4.7Hz,1H),2.70(d,J=12.7Hz,1H),2.45–2.23(m,3H),2.20–2.06(m,2H),1.97(dd,J=13.7,7.7Hz,1H),1.93–1.87(m,1H),1.81(t,J=8.7Hz,2H),1.67(tt,J=21.1,7.3Hz,5H),1.60–1.54(m,1H),1.46(ddd,J=21.5,14.3,8.1Hz,4H),1.21(d,J=6.2Hz,3H),0.93–0.83(m,1H).13CNMR(126MHz,CDCl3)δ172.60,165.77,164.18,147.65,136.47,130.33,117.89,76.20,71.82,71.76,61.95,60.09,55.60,49.49,44.21,42.85,41.06,40.46,33.96,33.72,31.68,28.23,28.00,26.55,24.70,20.68.ESI-MS:m/z529(M+Na)+
实施例9:4,7-O-二(烟酸)酰BFA(Ⅰ-17)的制备
向放置有磁力搅拌子的50mL的圆底烧瓶中加入10mL无水二氯甲烷(10ml),再加入BFA(100mg,0.36mmol),开始搅拌;后加入烟酸(92mg,0.75mmol)、EDC.HCl(205mg,108mmol)、DMAP(22mg,0.18mmol),于40℃加热反应24h,终止反应。反应液加入10ml二氯甲烷稀释,经水洗(2×10ml),饱和氯化钠溶液洗涤(2×10ml),合并的水相用乙酸乙酯萃取(1×30ml),合并有机相,无水硫酸钠干燥,过滤,浓缩得粗产物,粗产物在展开剂DCM/CH3OH=1:8的条件下经薄层层析分离获得化合物(Ⅰ-17)(Rf=0.8,收率89.4%)。
化合物表征:
化合物(Ⅰ-17):1HNMR(500MHz,CDCl3)δ9.21(d,J=1.6Hz,1H),9.16(d,J=1.7Hz,1H),8.75(ddd,J=11.0,4.8,1.6Hz,2H),8.26(ddt,J=23.0,7.9,1.9Hz,2H),7.40–7.35(m,2H),7.32(dd,J=15.7,3.4Hz,1H),5.74(qdd,J=15.7,8.3,3.1Hz,2H),5.57(ddd,J=10.4,3.1,1.8Hz,1H),5.43–5.38(m,1H),5.29(dd,J=15.1,9.6Hz,1H),4.87–4.78(m,1H),2.65–2.57(m,1H),2.46(ddd,J=15.1,9.7,5.6Hz,1H),2.39–2.31(m,1H),2.27–2.20(m,1H),2.04–1.94(m,1H),1.91–1.83(m,2H),1.80(ddd,J=10.1,6.0,2.5Hz,2H),1.75–1.67(m,1H),1.55–1.46(m,1H),1.20(d,J=1.8Hz,3H),0.98–0.85(m,1H).13CNMR(126MHz,CDCl3)δ165.17,164.48,163.89,153.72,153.31,150.75,150.64,146.10,136.99,136.86,135.17,131.55,126.02,125.22,123.30,123.21,118.71,77.09,76.31,71.83,49.86,43.98,39.92,38.36,33.92,31.67,26.30,20.58.ESI-MS:m/z513(M+Na)+
实施例9:7-O-(生物素)酰-BFA(Ⅰ-16)的制备
向放置有磁力搅拌子的50mL的圆底烧瓶中加入10mL无水二氯甲烷(10ml),再加入BFA(100mg,0.36mmol),开始搅拌;后加入1-金刚烷甲酸(135mg,0.75mmol)、EDC.HCl(205mg,108mmol)、DMAP(22mg,0.18mmol),于40℃加热反应24h,终止反应。反应液加入10ml二氯甲烷稀释,经水洗(2×10ml),饱和氯化钠溶液洗涤(2×10ml),合并的水相用乙酸乙酯萃取(1×30ml),合并有机相,无水硫酸钠干燥,过滤,浓缩得粗产物,粗产物在展开剂E/P=1:5的条件下经薄层层析分离获得化合物(Ⅰ-16)(Rf=0.2,收率10.6%)。
化合物表征:
化合物(Ⅰ-16)(:1HNMR(500MHz,CDCl3)δ7.37(dd,J=15.7,3.1Hz,1H),5.94(dd,J=15.7,1.9Hz,1H),5.72(ddd,J=14.9,10.2,4.4Hz,1H),5.22(dd,J=15.1,9.6Hz,1H),5.17–5.12(m,1H),4.92–4.85(m,1H),4.18–4.13(m,1H),2.41(dt,J=15.7,9.3Hz,1H),2.29(ddd,J=15.0,9.8,5.5Hz,1H),2.24–2.17(m,1H),2.02-1.95(m,4H,),1.90-1.80(m,8H),1.72-1.65(m,8H),1.61–1.50(m,3H),1.28(d,J=6.3Hz,3H),1.01–0.93(m,1H).13CNMR(126MHz,CDCl3)δ177.23,166.07,151.31,136.11,130.68,117.77,75.96,74.87,71.76,52.52,44.03,40.58,40.12,38.84,38.77,36.53,34.14,31.90,27.96,26.66,20.86.ESI-MS:m/z465(M+Na)+
实施例10:4,7-O-二(BOC-甘氨酸)酰BFA(Ⅰ-18)的制备
向放置有磁力搅拌子的50mL的圆底烧瓶中加入10mL无水二氯甲烷(10ml),再加入BFA(100mg,0.36mmol),开始搅拌;后加入BOC-甘氨酸(131mg,0.75mmol)、EDC.HCl(205mg,108mmol)、DMAP(22mg,0.18mmol),于40℃加热反应24h,终止反应。反应液加入10ml二氯甲烷稀释,经水洗(2×10ml),饱和氯化钠溶液洗涤(2×10ml),合并的水相用乙酸乙酯萃取(1×30ml),合并有机相,无水硫酸钠干燥,过滤,浓缩得粗产物,粗产物在展开剂E/P=1:5的条件下经薄层层析分离获得化合物(Ⅰ-18)(Rf=0.8,收率63.6%)。
化合物表征:
化合物(Ⅰ-18):1HNMR(500MHz,CDCl3)δ7.19(dd,J=15.7,3.4Hz,1H),5.70(ddd,J=14.7,9.9,4.4Hz,2H),5.31(ddd,J=10.0,3.1,1.7Hz,1H),5.24–5.16(m,1H),5.10(dd,J=15.4,5.0Hz,1H),4.88–4.80(m,1H),3.94(qd,J=18.4,5.7Hz,2H),3.85(d,J=5.5Hz,2H),2.50–2.41(m,1H),2.36–2.28(m,1H),2.15–2.04(m,2H),2.00(s,2H),1.84(dd,J=14.2,9.1Hz,2H),1.70(ddd,J=17.2,11.9,6.1Hz,2H),1.65–1.55(m,2H),1.54–1.47(m,1H),1.43(d,J=3.6Hz,18H),1.23(d,J=6.3Hz,3H),0.91(ddd,J=13.5,6.8,2.1Hz).13CNMR(126MHz,CDCl3)δ169.81,169.38,165.36,155.66,155.61,146.12,135.39,131.33,118.72,80.07,79.95,76.23,71.87,50.63,49.62,43.96,42.56,42.32,39.92,38.20,34.04,31.69,28.27,26.38,20.67.ESI-MS:m/z617(M+Na)+
此类化合物经体外检测分析具有明显的抗癌活性。筛选方法采用四氮唑盐还原法(MTT法)和磺酰罗丹明及蛋白染色体(SRB法),选用肿瘤细胞株TE-1,抑制效果如表1所示;另由Volsurfmodule(DS2.1)计算得到化合物的logP值、血脑屏障水平和肝毒性数值参见表1:
表1:BFA酯类化合物对肿瘤细胞TE-1的抑制活性
Claims (3)
1.一种布雷菲德菌素A酯类衍生物的制备方法,所述方法包括:将式(Ⅱ)所示的布雷菲德菌A溶于有机溶剂中,在惰性气体的保护下,加入式(Ⅲ)所示羧酸和催化剂,在25℃~100℃下搅拌反应8h~32h,反应结束后,反应液经分离纯化得到式(Ⅰ)所示布雷菲德菌素A酯类衍生物;
式(Ⅰ)中:
R1为-H或
R2为C1~C10烷基、C3~C10烯基、C3~C10炔基、苯基、萘基、取代苯基、噻吩基、吡啶基、所述取代苯基的取代基为羟基或卤素;
式(Ⅲ)中,
R2为C1~C10烷基、C3~C10烯基、C3~C10炔基、苯基、萘基、取代苯基、噻吩基、吡啶基、所述取代苯基的取代基为羟基或卤素;
所述有机溶剂为下列之一:N,N-二甲基甲酰胺、二氯甲烷、丙酮、四氢呋喃、乙腈、乙酸乙酯、氯仿、1,2-二氯乙烷、氯苯、对-二氯苯、苯、甲苯、正己烷、环己烷、石油醚、正戊烷、二甲苯;
所述催化剂为EDC/DMAP,所述布雷菲德菌A、式(Ⅲ)所示羧酸、EDC、DMAP物质的量之比为1:2.0~2.3:3:0.5。
2.如权利要求1所述的方法,其特征在于所述有机溶剂为二氯甲烷,用量为50~200mL/g布雷菲德菌A。
3.如权利要求2所述的方法,其特征在于所述反应在30~50℃下进行,反应时间20~25h。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210426089.9A CN103788053B (zh) | 2012-10-30 | 2012-10-30 | 布雷菲德菌素a酯类衍生物及其制备与应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210426089.9A CN103788053B (zh) | 2012-10-30 | 2012-10-30 | 布雷菲德菌素a酯类衍生物及其制备与应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103788053A CN103788053A (zh) | 2014-05-14 |
CN103788053B true CN103788053B (zh) | 2016-05-25 |
Family
ID=50664158
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201210426089.9A Active CN103788053B (zh) | 2012-10-30 | 2012-10-30 | 布雷菲德菌素a酯类衍生物及其制备与应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103788053B (zh) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104529991A (zh) * | 2014-12-24 | 2015-04-22 | 浙江工业大学 | 7-酰胺-布雷菲德菌素a衍生物及其制备与应用 |
CN104592208B (zh) * | 2014-12-24 | 2017-04-12 | 浙江工业大学 | 7‑n3‑布雷菲德菌素a及其1,2,3‑三氮唑类衍生物的制备与抗肿瘤应用 |
CN105153136B (zh) * | 2015-09-16 | 2018-11-13 | 浙江工业大学 | 布雷菲德菌素a酯类衍生物及其制备与应用 |
CN105294641B (zh) * | 2015-09-16 | 2017-11-03 | 浙江工业大学 | 布雷菲德菌素a硒酯衍生物及其制备与应用 |
CN106928210B (zh) * | 2017-03-10 | 2019-04-02 | 沈阳药科大学 | 布雷菲德菌素a的4-位呋咱no供体型衍生物的制备方法及用途 |
CN110028479B (zh) * | 2018-01-11 | 2021-02-26 | 沈阳药科大学 | 一类布雷菲德菌素a的7-位拼合氮芥衍生物的制备方法和用途 |
CN110028477B (zh) * | 2018-01-11 | 2021-02-26 | 沈阳药科大学 | 一类布雷菲德菌素a的4-位拼合氮芥衍生物的制备方法和用途 |
CN110028480B (zh) * | 2018-01-11 | 2021-01-29 | 沈阳药科大学 | 布雷菲德菌素a的4,7-位拼合美法仑类氮芥衍生物及其制备方法和用途 |
CN110028481B (zh) * | 2018-01-11 | 2021-01-29 | 沈阳药科大学 | 布雷菲德菌素a的7-位拼合美法仑类氮芥衍生物的制备方法和用途 |
CN110028482B (zh) * | 2018-01-11 | 2021-01-29 | 沈阳药科大学 | 布雷菲德菌素a的4-位拼合美法仑类氮芥衍生物及其制备方法和用途 |
CN110028478B (zh) * | 2018-01-11 | 2021-02-26 | 沈阳药科大学 | 一类布雷菲德菌素a的4,7-位拼合氮芥衍生物的制备方法和用途 |
CN112851648B (zh) * | 2019-11-28 | 2022-11-15 | 中国海洋大学 | 布雷菲德菌素a酯类衍生物在抗肿瘤药物中的应用 |
CN112851647B (zh) * | 2019-11-28 | 2023-01-13 | 中国海洋大学 | 布雷菲德菌素a衍生物及其制备方法和用途 |
CN112851622B (zh) * | 2019-11-28 | 2023-01-10 | 中国海洋大学 | 一种大环内酯布雷菲德菌素a酯类衍生物及应用 |
CN112057461A (zh) * | 2020-09-15 | 2020-12-11 | 东北农业大学 | 多拉菌素在治疗食管癌中的应用 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102399210B (zh) * | 2011-11-18 | 2014-07-02 | 浙江工业大学 | 一种从发酵液中分离提取高纯度布雷菲德菌素a的方法 |
CN102731573B (zh) * | 2012-06-28 | 2015-06-03 | 天津林美科技有限公司 | 布雷菲德菌素a的羟基磷酸氨基酸酯类衍生物及其制备方法和应用 |
-
2012
- 2012-10-30 CN CN201210426089.9A patent/CN103788053B/zh active Active
Non-Patent Citations (1)
Title |
---|
SYNTHESIS AND ACTIVITY OF BREFELDIN A ANALOGS AS INDUCERS OF CANCER CELL DIFFERENTIATION AND APOPTOSIS;Ji-Wen ZHU,et al.;《Bioorganic & Medicinal Chemistry Letters》;19971231;第7卷(第2期);139-144 * |
Also Published As
Publication number | Publication date |
---|---|
CN103788053A (zh) | 2014-05-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103788053B (zh) | 布雷菲德菌素a酯类衍生物及其制备与应用 | |
CN111925381B (zh) | 一种巴洛沙韦关键中间体的合成方法 | |
CN106928236A (zh) | 一种瑞博西尼的合成工艺 | |
CN102947312B (zh) | 生产啶南平衍生物的方法 | |
CN106946972B (zh) | 一种具有抗肿瘤活性的熊果酸衍生物及其制备方法 | |
CN104447934A (zh) | 一种醋酸阿比特龙的纯化方法 | |
CN103724258B (zh) | 一种索拉非尼的制备方法 | |
CN102348706A (zh) | 生产啶南平衍生物的方法 | |
CN106365986A (zh) | 化合物及其制备方法和在合成布瓦西坦中的用途 | |
CN102850283A (zh) | 一类含三唑基的氨基二硫代甲酸酯化合物、 制备方法及其应用 | |
CN105541834B (zh) | 一种2‑苯基咪唑并[1,2‑a]吡啶类化合物的合成方法 | |
CN108218798B (zh) | Apabetalone的制备方法 | |
CN106946880A (zh) | 一种制备瑞博西尼中间体的方法 | |
CN101768075B (zh) | 15-羰基甜菊醇衍生物和盐、制备方法及用途 | |
CN106916116A (zh) | 一种高收率含α,β不饱和酮的1,2,4‑噁二唑类化合物的环保制备方法 | |
WO2008093853A1 (ja) | マクロライド系化合物の固体およびその製造法並びにその医薬組成物 | |
CN107235853B (zh) | 一种用于制备鸡骨草甲素及其异构体的合成方法 | |
CN103374049B (zh) | 一种制备5,6,4’-三羟基黄酮-7-0-d-葡萄糖醛酸的方法 | |
CN107216361B (zh) | 索利霉素的制备方法 | |
CN104177327A (zh) | 6-氨基-2-硫杂螺[3,3]庚烷盐酸盐的制备方法 | |
CN101407459B (zh) | 单羟基-2-酰基苯乙酸酯及其制备方法与应用 | |
CN114716497A (zh) | 一种制备脱氧胆酸的方法 | |
CN113121411A (zh) | 细胞松弛素类化合物及细胞松弛素类衍生物的合成方法 | |
CN104513147B (zh) | 芴乙酮衍生物的制备方法 | |
CN113135931B (zh) | 一种细胞松弛素类化合物flavipesine A的合成方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant |